Tag Archives: Intellectual Property

Measuring the Impact of Innovation

USPTO

By Joe Allen, President, Allen and Associates It’s always an indication of interest and importance in a topic when a panel draws a standing room only crowd. And that was the case with the Measuring the Impacts of Innovation: What is the Future of Tech Transfer? session at the 2012 BIO International Convention. The panel focused on the need to help policy makers, institutions and the public identify appropriate measures for how publicly funded R&D Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Gene Patent Discussion Should Include Industrial, Environmental, & Ag Biotech

myriad-more

Twenty-three industrial and agricultural biotech companies, ranging from development-stage businesses to all of the largest players in the field, sent a letter to the Solicitor General expressing concern over the pending appeal in the Myriad “gene patents” case.  The companies wrote the letter to correct the myopic view that this case is only about human genetic diagnostics. The case could potentially adversely impact agricultural and industrial biotechnology, whose activities are far removed from the clinical Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

India Compulsory License: A Times of India Article Says It’s Not Helping the Poor

india-btn

India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with the stated goal of providing access to India’s poor. However, the Times of India recently ran the article Cheap generics drugs no panacea for India’s poorest, quickly dispelling this myth: “The compulsory license system might not really work because poor people cannot even afford the discounted price,” said G. Balachandhran, former head of the National Pharmaceutical Pricing Authority (NPPA), India’s drug Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

BIO IP Counsels Conference Agenda Topics

bio-ip-events-btn

Join us in Austin for BIO’s Intellectual Property Counsels Committee Conference on April 16-18.  Agenda topics are below. The Decline of Process Patents: This session will examine the enforceability of process claims and how it has led to the recent controversy around divided infringement. Unlike claims to machines, manufactures, and compositions, process claims can be divided up by different actors, or by jurisdiction, and conceivably even by time.  Right now the focus is on different Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Brazilian Innovation: A Patent Success

plant

The story of Acheflan highlights the role of patents in homegrown innovation in developing countries.  Professor Michael Ryan of George Washington University Law School reviewed several case studies (including Acheflan) in Brazil that highlight the differences in biomedical innovation both pre- and post-intellectual property reforms. In the early 1980’s, Ache Laboratorios Farmaceuticos (a Brazilian generics manufacturer) became aware of a plant that grew near coastal cities that local fishermen would mash into an oil rub Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,